Preview

Сибирский научный медицинский журнал

Advanced search

ANTIMICROBIAL RESISTANCE OF Klebsiella pneumonia ISOLATES IN REPUBLIC OF SAKHA (YAKUTIA)

https://doi.org/10.15372/SSMJ20180618

Abstract

The aim of the study was to evaluate the susceptibility to antibiotics of Klebsiella pneumoniae isolates in the Republic of Sakha (Yakutia), according to the AMRmap database. Material and methods. Data of online platform AMRmap in 2010-2016 have been used for evaluation of the sensitivity of K. pneumoniae isolates to antibiotics. Results and discussion. K. pneumoniae isolates comprised 35,7 % of all bacterial nosocomial isolates ( n = 195) and 30,1 % of community-acquired isolates ( n = 382) respectively. Most of the isolates were insusceptible to common antibiotics: aminoglycosides (gentamicin, tobramycin, netilmicin) - 50-78 %; chloramphenicol - 36-43 %, cephalosporins III-V generation (ceftazidime, cefotaxime, zepefin, ceftarolin) - 83-100 %, penicillin drugs with inhibitor of beta-lactamases (ticarcillin-clavulanate, amoxicillin-clavulanate) - 83-98 % monobactams (aztreonam) - 87-95 %, semi-synthetic penicillins of broad spectrum of action (ampicillin) - 100 %, sulfonamides (trimethoprim-sulfamethoxazole) - 53-76 %, fluoroquinolones (ciprofloxacin) - 77 %. At present the next preparations can be effective against K. pneumonia: amikacin (sensitivity 96-100 %), ceftazidime-avibactam (95-97 %), tigecycline (97-100 %), carbapenems (87-97 %), in some cases, phosphomycin (77 %) and piperacillin-tazobactam (64-71 %). Conclusion. The spectrum of drugs for the treatment of infections caused by K. pneumoniae is extremely limited. The further spread of resistance to carbapenems poses a threat of ineffectiveness in the treatment of severe infections. In these conditions, measures are needed to limit the unjustified use of carbapenems. The indicators of resistance of K. pneumoniae to antibiotics should be taken into account not only for the effective treatment of patients, but also for optimizing the costs of regional health care, for example when planning procurement of medicines for hospitals

About the Authors

O. M. Egorova
Medical Institute of North-Eastern Federal University n.a. M.K. Ammosov
Russian Federation


E. P. Ignateva
Medical Institute of North-Eastern Federal University n.a. M.K. Ammosov
Russian Federation


I. Y. Isaeva
Medical Institute of North-Eastern Federal University n.a. M.K. Ammosov
Russian Federation


G. V. Filippova
Medical Institute of North-Eastern Federal University n.a. M.K. Ammosov
Russian Federation


T. M. Klimova
Medical Institute of North-Eastern Federal University n.a. M.K. Ammosov
Russian Federation


References

1. Кузьменков А.Ю., Трушин И.В., Авраменко А.А., Эйдельштейн М.В., Дехнич А.В., Козлов Р.С. AMRmap: Интернет-платформа мониторинга антибиотикорезистентности // Клин. микробиол. и антимикроб. химиотерапия. 2017. 19. (2). 84-90.

2. Сухорукова М.В., Эйдельштейн М.В., Склеенова Е.Ю., Иванчик Н.В., Тимохова А.В., Дехнич А.В., Козлов Р.С., исследовательская группа «МАРАФОН». Антибиотикорезистентность нозокомиальных штаммов Enterobacteriaceae в стационарах России : результаты многоцентрового эпидемиологического исследования МАРАФОН в 2011-2012 гг. // Клин. микробиол. и антимикроб. химиотерапия. 2014. 16. (4). 254-265.

3. Эпиднадзор за устойчивостью к противомикробным препаратам в Центральной Азии и Восточной Европе. 2016. ВОЗ. Режим доступа: http://www.euro.who.int/ru/publications/abstracts/central-asian-and-eastern-european-surveillance-of-antimicrobial-resistance.-annual-report-2016 (accessed July 20, 2018).

4. Albiger B., Glasner C., Struelens M., Grundmann H., Monnet D., the European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries // Euro Surveill. 2015. 20. (45). pii 30062.

5. AMRmap. [Online]. 2018. Available at: http://map.antibiotic.ru/ (accessed July 20, 2018).

6. Antimicrobial resistance: global report on surveillance, 2014. World Health Organization. 2014. [Online]. April, 2014 Available at: http://www.who.int/drugresistance/documents/surveillancereport/en/ (accessed July 20, 2018).

7. Chung P.Y. The emerging problems of Klebsiella pneumoniae infections: carbapenem resistance and biofilm formation // FEMS Microbiol. Lett. 2016. 363. (20). 1-6.

8. Global antimicrobial resistance surveillance system (GLASS) report: early implementation 2016-2017. World Health Organization. 2017. Available at: http://www.who.int/glass/resources/publications/early-implementation-report/en/ (accessed July 20, 2018).

9. Kidd T.J., Mills G., Sá-Pessoa J., Dumigan A., Frank Ch.G., Insua J.L., Ingram R., Hobley L., Bengoechea J.A. A Klebsiella pneumoniae antibiotic resistance mechanism that subdues host defences and promotes virulence // EMBO Mol. Med. 2017. 9. (4). 430-447.

10. Navon-Venezia S., Kondratyeva K., Carattoli A. Klebsiella pneumoniae: a major worldwide source and shuttle for antibiotic resistance // FEMS Microbiol. Rev. 2017. 41. (3). 252-275.


Review

Views: 325


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2410-2512 (Print)
ISSN 2410-2520 (Online)